Keytruda improves survival in first-line squamous NSCLC

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab plus chemotherapy met the primary endpoints of improving progression-free survival (PFS) and overall survival (OS) in the Phase III KEYNOTE-407 trial as first-line treatment of metastatic squamous non-small cell lung cancer

Read the full 391 word article

User Sign In